📰 Mark Gergen News
Mark Gergen News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mark Gergen. Real-time updates on events, politics, business and more.
October 9, 2023
Mark Gergen to assume role of Executive Chairman of the Board of Directors of Poseida; Kristin Yarema, Ph.D., currently President, Cell Therapy, to be appointed President and CEO SAN DIEGO, Oct. 9,...
October 9, 2023
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
August 8, 2023
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
August 8, 2023
Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic engineering technologies Astellas to invest a total of $50 million to acquire approximately 8.8% of Poseida and to receive a right of exclusive negotiation and first refusal for any potential partnering of P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy product candidate for solid tumors Astellas will have the right to designate an obser...
August 7, 2023
Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic engineering technologies Astellas to invest a...
August 7, 2023
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
August 7, 2023
Global pharmaceutical firm Astellas, which operates a $100 million gene therapy manufacturing plant in Sanford, is investing $50 million in San Diego-based Poseida Therapeutics.
April 13, 2023
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
February 22, 2023
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
January 31, 2023
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...